| 查看: 234 | 回复: 0 | |||
ienjoysun银虫 (著名写手)
|
[交流]
Novartis in talks to buy Gamida Cell for up to $600 million: report
|
|
Novartis in talks to buy Gamida Cell for up to $600 million: report (Ref: Globes, Jewish Business News, Fidelity) March 18th, 2014 By: Matthew Dennis Tags: Top Story StemEx Clal Biotechnology Gamida Cell Novartis Corporate Affairs Mergers & Acquisitions According to sources close to the matter, Novartis is in advanced discussions to buy Gamida Cell for as much as $600 million, Globes reported Tuesday. Elbit Medical Technologies, which has a 30.8-percent stake in Gamida, confirmed an offer from an unnamed company, noting that it includes a "significant immediate payment and additional future payments totalling hundreds of millions of dollars." Clal Biotechnology, which holds around 22 percent of Gamida, added that the bid was received on March 7. Gamida is developing stem cell therapies for a variety of conditions, including its StemEx treatment, which is being evaluated as part of a transplant regimen for patients with high-risk leukaemia and lymphoma. According to Elbit and Clal, future payments under the deal would depend on meeting development, registration and sales milestones. Globes noted that although talks with Novartis are at an advanced stage, Gamida has not abandoned plans for an initial public offering. The newspaper said that the valuation for the IPO is lower than the potential value of an acquisition, which would likely be the preferred option. http://www.firstwordpharma.com/node/1196136#axzz2wOds3Uam |
» 猜你喜欢
考博求博导收留
已经有0人回复
多糖提取纯化结构表征和活性
已经有0人回复
药物学论文润色/翻译怎么收费?
已经有109人回复
考博求助
已经有1人回复
终于攒够发帖子的金币了,让我试试
已经有1人回复
考博求助
已经有0人回复
申博自荐 药学生物学分子生物学
已经有2人回复
双环[1.1.0]丁烷衍生物合成
已经有4人回复
英国贝尔法斯特女王大学药物递送方向招CSC博士生
已经有1人回复
Materials Today Chemistry和AMH哪个投稿快啊
已经有0人回复
考博求助,求博导收留
已经有0人回复










回复此楼